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Background: The aim of this study was to assess behavioural recovery from the patient’s perspective as
a prespecified secondary outcome in a multicentre parallel-group randomized clinical trial comparing
ultrasound-guided foam sclerotherapy (UGFS), endovenous laser ablation (EVLA) and surgery for the
treatment of primary varicose veins.
Methods: Participants were recruited from 11 UK sites as part of the CLASS trial, a randomized trial of
UGFS, EVLA or surgery for varicose veins. Patients were followed up 6 weeks after treatment and asked
to complete the Behavioural Recovery After treatment for Varicose Veins (BRAVVO) questionnaire. This
is a 15-item instrument that covers eight activity behaviours (tasks or actions an individual is capable of
doing in an idealized situation) and seven participation behaviours (what the individual does in an everyday,
real-world situation) that were identified to be important from the patient’s perspective.
Results: A total of 798 participants were recruited. Both UGFS and EVLA resulted in a significantly
quicker recovery compared with surgery for 13 of the 15 behaviours assessed. UGFS was superior to
EVLA in terms of return to full-time work (hazard ratio 1⋅43, 95 per cent c.i. 1⋅11 to 1⋅85), looking after
children (1⋅45, 1⋅04 to 2⋅02) and walks of short (1⋅48, 1⋅19 to 1⋅84) and longer (1⋅32, 1⋅05 to 1⋅66) duration.
Conclusion: BothUGFS and EVLA resulted inmore rapid recovery than surgery, andUGFSwas superior
to EVLA for one-quarter of the behaviours assessed. The BRAVVO questionnaire has the potential to
provide importantmeaningful information to patients about their early recovery andwhat theymay expect
to be able to achieve after treatment.
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Introduction
Minimally invasive treatments for varicose veins such as
ultrasound-guided foam sclerotherapy (UGFS) and ther-
mal ablation techniques have become widely used alter-
natives to surgery for the treatment of varicose veins.
One of the advantages of these techniques is the reported
quicker return to normal activities, particularly following
UGFS1–3. However, it is unclear whether thermal abla-
tion, in particular endovenous laser ablation (EVLA), is
also associated with a clinically significant quicker return
to normal activities compared with surgery; some studies4,5
have shown an earlier return and others2,6–8 no difference.
Until recently, there was no standard means of assessing
recovery from the patient’s perspective. This led to the use
of varying definitions such as return to ‘normal activities’,
‘full activity’, ‘daily activity’ or ‘basic physical activities’
and/or ‘return to work’ in previous studies. This lack
of standardization led the authors to develop a 15-item
questionnaire to assess distinct aspects of normal activi-
ties that were identified as important by patients9 – the
Behavioural Recovery After treatment for Varicose Veins
(BRAVVO) questionnaire.
This paper reports behavioural recovery results from
a multicentre parallel-group randomized clinical trial
(CLASS, Comparison of LAser, Surgery and foam
Sclerotherapy) that compared the clinical efficacy and
cost-effectiveness of three treatment modalities: UGFS,
EVLA with delayed foam sclerotherapy to residual vari-
cosities if required, and surgery. Behavioural recovery was
one of the prespecified secondary outcomes of the CLASS
trial. The clinical and cost-effectiveness results have been
reported elsewhere10,11.
Methods
Patients were recruited from 11 centres in the UK
between November 2008 and October 2012. This study
© 2016 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. BJS 2016; 103: 374–381
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited and is not used for commercial purposes.
Behavioural recovery after treatment for varicose veins 375
1. Bending the leg(s) (without discomfort):
I don’t normally do this 
I normally do this, but haven’t done so since my treatment
I have done this since my treatment. I did it for the first time:
on the day of my
treatment
days after my
treatment
weeks after my
treatmentOROR
Fig. 1 Question layout
Eligible patients n = 3369
Allocated to UGFS n = 292
Postrandomization exclusions n = 6
Included in trial n = 286
Allocated to surgery n = 294
Postrandomization exclusions n = 5
Included in trial n = 289
Allocated to EVLA n = 212
Postrandomization exclusions n = 2
Included in trial n = 210
Declined to participate n = 2571
Treatment received
 UGFS n = 265 (92·7%)
 Surgery n = 4 (1·4%)
 EVLA n =  6 (2·1%)
 No treatment n = 11 (3·8%)
Treatment received
 UGFS n = 7 (2·4%)
 Surgery n = 252 (87·2%)
 EVLA n = 8 (2·8%)
 No treatment n = 22 (7·6%)
Treatment received
 UGFS n = 0 (0%)
 Surgery n = 2 (1·0%)
 EVLA n = 203 (96·7%)
 No treatment n = 5 (2·4%)
6-week follow-up
 Questionnaire n = 247 (86·4%)
 BRAVVO n = 240 (83·9%)
 Withdrawn n = 12 (4·2%)
6-week follow-up
 Questionnaire n = 237 (82·0%)
 BRAVVO n = 233 (80·6%)
 Withdrawn n = 29 (10·0%)
6-week follow-up
 Questionnaire n = 186 (88·6%)
 BRAVVO n = 182 (86·7%)
 Withdrawn n = 6 (2·9%)
Fig. 2 CONSORT diagram for the trial. Reasons for postrandomization exclusion included: recurrent varicose veins and veins larger
than 15 mm. Reasons for withdrawal from follow-up included: patient decided not to proceed with treatment (and also declined
follow-up), declined follow-up after treatment or did not wish to complete questionnaires. UGFS, ultrasound-guided foam
sclerotherapy; EVLA, endovenous laser ablation
(ISRCTN51995477) had research ethics committee and
Medicines and Healthcare products Regulatory Authority
approval. Eight centres randomized participants to one of
three treatment options, and three centres offered only
UGFS and surgery. Participants were randomized between
the treatments with even allocation, using a minimization
algorithm that included centre, age (less than 50 years, 50
years or more), sex, great saphenous vein (GSV) or small
saphenous vein (SSV) reflux, and unilateral or bilateral
disease. Inclusion criteria were: age over 18 years; primary
unilateral or bilateral symptomatic varicose veins (Clinical
Etiologic Anatomic Pathophysiological (CEAP) grade
C2 or above); GSV and/or SSV involvement; and reflux
exceeding 1 s on duplex ultrasonography. Exclusion criteria
were: current deep vein thrombosis; acute superficial vein
thrombosis; a GSV or SSV diameter smaller than 3mm or
larger than 15mm; tortuous veins considered unsuitable
for EVLA or stripping; and contraindications to UGFS or
to general/regional anaesthesia that would be required for
surgery.
Treatments
The treatments have been described in detail elsewhere9,10.
For UGFS, foam was produced using the Tessari
technique12 using a ratio of 0⋅5ml sodium tetradecyl
sulphate to 1⋅5ml air (3 per cent for GSV/SSV truncal
veins, 1 per cent for varicosities; maximum 12ml foam
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Table 1 Demographic details at recruitment
EVLA UGFS Surgery
(n=210) (n=286) (n= 289)
Age (years)* 49⋅7 (18–80) 49⋅0 (19–78) 49⋅2 (22–85)
Sex ratio (F :M) 120 : 90 162 : 124 163 : 126
Body mass index (kg/m2)* 27⋅0 (17–42) 27⋅1 (17–44) 27⋅7 (17–44)
Unilateral disease 153 (72⋅9) 215 (75⋅2) 196 (67⋅8)
Employment status
Self-employed 21 (10⋅2) 37 (13⋅0) 29 (10⋅3)
Employed 120 (58⋅3) 169 (59⋅3) 179 (63⋅5)
Other 65 (31⋅6) 79 (27⋅7) 74 (26⋅2)
Unknown 4 1 7
Saphenous vein involvement
Great saphenous 182 (86⋅7) 232 (81⋅1) 239 (82⋅7)
Small saphenous 14 (6⋅7) 21 (7⋅3) 21 (7⋅3)
Great and small saphenous 14 (6⋅7) 33 (11⋅5) 29 (10⋅0)
Deep vein reflux 28 of 205 (13⋅7) 47 of 280 (16⋅8) 25 of 282 (8⋅9)
CEAP classification
C2, varicose veins over 3mm 113 (54⋅1) 169 (59⋅1) 147 (51⋅2)
C3, oedema 28 (13⋅4) 35 (12⋅2) 39 (13⋅6)
C4, skin/subcutaneous changes 56 (26⋅8) 74 (25⋅9) 90 (31⋅4)
C5/C6, healed/active venous ulcer 12 (5⋅7) 8 (2⋅8) 11 (3⋅8)
Unknown 1 0 2
Values in parentheses are percentages unless indicated otherwise; *values are mean (range). EVLA, endovenous laser ablation; UGFS, ultrasound-guided
foam sclerotherapy; CEAP, Clinical Etiologic Anatomic Pathophysiologic.
per session). EVLA of GSVs/SSVs was performed under
local anaesthetic, and patients were offered UGFS to
any residual varicosities at 6-week follow-up if required,
with the exception of one centre that performed con-
current phlebectomies. Surgery in the form of proximal
GSV/SSV ligation and stripping (all GSV) and con-
current phlebectomies was performed under general or
regional anaesthetic as a day-case procedure. Compression
stockings were applied after all three treatments.
Post-treatment activity
All participants were given a study patient information
leaflet (PIL), which recommended a return to all normal
activities as soon as they were able, but that strenuous
activity/contact sport should be avoided for 1–2weeks.
The PIL specifically stated that following EVLA or UGFS
‘most people are able to return to work within 2–3 days
of treatment, but some people go back the following day
or even the same day’, and that following surgery ‘people
can return to office or sedentary work after 2–3 days; and
that most people will be back at work within a week after
surgery to one leg and 2 weeks after surgery to both legs;
but there is no reason to remain off work as long if it can
be managed with reasonable comfort’. Participants under-
going UGFS or EVLA were advised to wear compression
stocking for 10 days constantly (day and night). Those in
the surgery group were advised that bandages would be
removed the day after operation, following which they
should wear a stocking for 10 days, but that it was reason-
able to remove the stocking after 4 or 5 days, providing
that they were active.
Data collection
The participants were asked to complete the BRAVVO
questionnaire along with other study questionnaires
(Aberdeen Varicose Vein Questionnaire, EQ-5D™ (Euro-
QoL, Rotterdam, The Netherlands) and Short Form
36 (QualityMetric, Lincoln, Rhode Island, USA)) at the
6-week follow-up appointment. Participants who failed to
attend the 6-week appointment were sent the questionnaire
to complete at home.
The BRAVVO questionnaire was developed as an instru-
ment to assess the activity and participation components
of the World Health Organization International Classi-
fication of Disability and Function model13. Variation in
activity and participation is not fully explained by impair-
ment and so these constructs are important additional
indicators of health outcome. An interview study involving
17 patients who had recently undergone varicose vein
treatment was carried out to identify normal activities and
‘milestone’ behaviours to incorporate into the question-
naire. In addition to sampling from the three treatment
options, diversity sampling was used in an attempt to gain
a mix of sex, age and rural–urban location. Seventeen
interview transcripts were content-analysed in four stages
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Table 2 Behavioural recovery: ultrasound-guided foam sclerotherapy versus surgery
Time until specified proportion of
participants could carry out behaviour (days)*
Proportion carrying
out behaviour (%) UGFS Surgery Hazard ratio†
Activity items
Bending the legs without discomfort 50 3⋅0 4⋅6 1⋅38 (1⋅14, 1⋅67)
90 14⋅1 21⋅3
Lifting heavy objects without discomfort 50 4⋅8 9⋅8 1⋅97 (1⋅59, 2⋅44)
90 16⋅9 34⋅5
Moving from standing to sitting without discomfort 50 1⋅9 3⋅7 1⋅63 (1⋅35, 1⋅97)
90 9⋅3 17⋅5
Standing still for a long time (>15 min ) without discomfort 50 3⋅9 7⋅1 1⋅67 (1⋅36, 2⋅05)
90 15⋅8 28⋅7
Walking short distances (<20 min ) without discomfort 50 1⋅9 4⋅4 2⋅00 (1⋅65, 2⋅42)
90 8⋅2 19⋅1
Walking long distances (>20 min) 50 4⋅5 8⋅0 1⋅76 (1⋅45, 2⋅14)
90 15⋅2 27⋅1
Having a bath or shower 50 5⋅4 4⋅9 0⋅85 (0⋅70, 1⋅03)
90 11⋅4 10⋅3
Driving a car 50 4⋅1 7⋅0 1⋅78 (1⋅45, 2⋅19)
90 12⋅4 21⋅1
Participation items
Doing housework 50 2⋅1 4⋅5 2⋅10 (1⋅72, 2⋅56)
90 7⋅3 15⋅7
Looking after children 50 1⋅2 3⋅5 2⋅20 (1⋅61, 3⋅00)
90 6⋅2 17⋅9
Wearing clothes that show the legs 50 12⋅4 12⋅8 1⋅03 (0⋅78, 1⋅35)
90 56⋅6 58⋅7
Partial return to normal work/employment 50 4⋅4 9⋅9 2⋅16 (1⋅72, 2⋅72)
90 15⋅4 34⋅2
Full return to normal work/employment 50 4⋅8 11⋅7 2⋅56 (2⋅05, 3⋅21)
90 14⋅9 36⋅2
Going out socially 50 7⋅1 9⋅3 1⋅29 (1⋅06, 1⋅57)
90 25⋅8 34⋅0
Sporting activity or exercise 50 15⋅7 21⋅8 1⋅33 (1⋅05, 1⋅68)
90 62⋅6 86⋅7
Values in parentheses are 95 per cent c.i. *The 50 per cent value is equivalent to the median time to return to the behaviour. †A hazard ratio greater than
1⋅00 shows that return to the behaviour took longer in the surgery arm. UGFS, ultrasound-guided foam sclerotherapy.
to identify appropriate items to include in a questionnaire.
Full details of this process have been published previously9.
The BRAVVO questionnaire assesses the time taken
for patients to return to performing 15 behaviours: eight
‘activity’ behaviours (tasks or actions an individual is
capable of doing in an idealized situation) and seven
‘participation’ behaviours (what the individual does in an
everyday, real-world situation) that were identified to be
important from the patient’s perspective9. Fig. 1 shows the
question layout.
Statistical analysis
Data from the BRAVVO questionnaire were analysed
within an interval-censored time-to-event framework
using flexible parametric survival models14. For each
behaviour item, each participant’s response was converted
into the number of days to return to that behaviour. If
a participant indicated that return to the behaviour was
on the day of the procedure, this was assumed to be
interval-censored between day 0 and day 1. If a participant
indicated return to the behaviour was after a number of
weeks, not days, this was assumed to be interval-censored
between the previous week and the week indicated. For
example, if a participant reported 5weeks, it was assumed
that the return to the behaviour took place between 28
and 35 days. A participant who indicated that they had not
returned to a behaviour that they usually performed was
right-censored at 42 days. Participants who indicated that
they did not normally perform a specific behaviour were
not included in analysis of that behaviour. No missing data
were imputed.
Data are reported as the number of days for 50 and
90 per cent of participants to return to each behaviour,
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Table 3 Behavioural recovery: endovenous laser ablation versus surgery
Time until specified proportion of
participants could carry out behaviour (days)*
Proportion carrying
out behaviour (%) EVLA Surgery Hazard ratio†
Activity items
Bending the legs without discomfort 50 2⋅7 4⋅6 1⋅49 (1⋅19, 1⋅75)
90 12⋅6 21⋅3
Lifting heavy objects without discomfort 50 5⋅9 9⋅8 1⋅79 (1⋅39, 2⋅27)
90 20⋅5 34⋅5
Moving from standing to sitting without discomfort 50 2⋅2 3⋅7 1⋅56 (1⋅27, 1⋅96)
90 10⋅4 17⋅5
Standing still for a long time (>15 min) without discomfort 50 4⋅8 7⋅1 1⋅41 (1⋅11, 1⋅79)
90 20⋅0 28⋅7
Walking short distances (<20 min) without discomfort 50 3⋅0 4⋅4 1⋅30 (1⋅04, 1⋅61)
90 13⋅2 19⋅1
Walking long distances (>20 min) 50 5⋅6 8⋅0 1⋅53 (1⋅06, 1⋅67)
90 19⋅8 27⋅1
Having a bath or shower 50 5⋅5 4⋅9 0⋅74 (0⋅59, 0⋅93)
90 12⋅8 10⋅3
Driving a car 50 4⋅4 7⋅0 1⋅82 (1⋅43, 2⋅33)
90 12⋅7 21⋅1
Participation items
Doing housework 50 2⋅5 4⋅5 1⋅89 (1⋅49, 2⋅38)
90 8⋅4 15⋅7
Looking after children 50 1⋅9 3⋅5 1⋅61 (1⋅15, 2⋅27)
90 8⋅8 17⋅9
Wearing clothes that show the legs 50 14⋅6 12⋅8 0⋅97 (0⋅69, 1⋅35)
90 75⋅1 58⋅7
Partial return to normal work/employment 50 6⋅3 9⋅9 1⋅75 (1⋅33, 2⋅27)
90 21⋅1 34⋅2
Full return to normal work/employment 50 7⋅7 11⋅7 1⋅79 (1⋅37, 2⋅27)
90 23⋅5 36⋅2
Going out socially 50 6⋅9 9⋅3 1⋅41 (1⋅12, 1⋅75)
90 23⋅9 34⋅0
Sporting activity or exercise 50 14⋅2 21⋅8 1⋅47 (1⋅12, 1⋅92)
90 55⋅5 86⋅7
Values in parentheses are 95 per cent c.i. *The 50 per cent value is equivalent to the median time to return to the behaviour. †A hazard ratio greater than
1⋅00 shows that return to the behaviour took longer in the surgery arm. EVLA, endovenous laser ablation.
estimated from the parametric survival models (the 50 per
cent value represents the median time to return to this
behaviour). Extrapolation beyond the 42-day cut-off was
performed for behaviours where 90 per cent of participants
had not returned to the behaviour by 42 days. Treatment
effects are presented as hazard ratios with associated 95
per cent c.i. All analyses were carried out in Stata® 1215.
Flexible parametric survival models were fitted using the
stpm package16.
Results
Seven hundred and ninety-eight participants were
recruited, of whom 13 were ineligible (for example
because they had recurrent veins or veins larger than
15mm in diameter) after randomization and were con-
sidered postrandomization exclusions (Fig. 2). The groups
were well balanced in terms of demographic characteristics
at baseline, but there was an increased incidence of deep
venous reflux in the foam group compared with the surgery
group (P= 0⋅005) (Table 1). Of the 670 participants who
completed the 6-week questionnaire, 655 completed at
least one of the BRAVVO questions. Completion rates
were slightly lower for the questions about going out
socially (74⋅8 per cent) and sporting activity (66⋅0 per
cent), which may not have been relevant to all participants.
For all behaviours, except wearing clothes that show the
leg, going out socially and sporting activities, over 95 per
cent of participants had returned to normal behaviour
within 6 weeks of intervention.
Ultrasound-guided foam sclerotherapy versus
surgery
Participants randomized to UGFS recalled being able
to carry out 13 of the 15 behaviours significantly more
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Table 4 Behavioural recovery: endovenous laser ablation versus ultrasound-guided foam sclerotherapy
Time until specified proportion of
participants can carry out behaviour (days)*
Proportion carrying
out behaviour (%) EVLA UGFS Hazard ratio†
Activity items
Bending the legs without discomfort 50 2⋅7 3⋅0 0⋅94 (0⋅75, 1⋅17)
90 12⋅6 14⋅1
Lifting heavy objects without discomfort 50 5⋅9 4⋅8 1⋅11 (0⋅87, 1⋅42)
90 20⋅5 16⋅9
Moving from standing to sitting without discomfort 50 2⋅2 1⋅9 1⋅12 (0⋅90, 1⋅40)
90 10⋅4 9⋅3
Standing still for a long time (>15 min) without discomfort 50 4⋅8 3⋅9 1⋅14 (0⋅90, 1⋅44)
90 20⋅0 15⋅8
Walking short distances (<20 min) without discomfort 50 3⋅0 1⋅9 1⋅48 (1⋅19, 1⋅84)
90 13⋅2 8⋅2
Walking long distances (>20 min) 50 5⋅6 4⋅5 1⋅32 (1⋅05, 1⋅66)
90 19⋅8 15⋅2
Having a bath or shower 50 5⋅5 5⋅4 1⋅19 (0⋅96, 1⋅48)
90 12⋅8 11⋅4
Driving a car 50 4⋅4 4⋅1 0⋅95 (0⋅74, 1⋅21)
90 12⋅7 12⋅4
Participation items
Doing housework 50 2⋅5 2⋅1 1⋅03 (0⋅82, 1⋅29)
90 8⋅4 7⋅3
Looking after children 50 1⋅9 1⋅2 1⋅45 (1⋅04, 2⋅02)
90 8⋅8 6⋅2
Wearing clothes that show the legs 50 14⋅6 12⋅4 1⋅17 (0⋅83, 1⋅64)
90 75⋅1 56⋅6
Partial return to normal work/employment 50 6⋅3 4⋅4 1⋅17 (0⋅89, 1⋅52)
90 21⋅1 15⋅4
Full return to normal work/employment 50 7⋅7 4⋅8 1⋅43 (1⋅11, 1⋅85)
90 23⋅5 14⋅9
Going out socially 50 6⋅9 7⋅1 0⋅88 (0⋅70, 1⋅10)
90 23⋅9 25⋅8
Sporting activity or exercise 50 14⋅2 15⋅7 0⋅80 (0⋅61, 1⋅04)
90 55⋅5 62⋅6
Values in parentheses are 95 per cent c.i. *The 50 per cent value is equivalent to the median time to return to the behaviour. †A hazard ratio greater than
1⋅00 shows that return to the behaviour took longer in the endovenous laser ablation (EVLA) arm. UGFS, ultrasound-guided foam sclerotherapy.
quickly than those randomized to surgery (Table 2). The
two behaviours for which there was no evidence of a dif-
ference in the time to recover between the trial arms were
‘having a bath or shower’ and ‘wearing clothes that show
the legs’. In general, the median time to return to the activ-
ity behaviours was 5 days or less for those randomized to
UGFS and up to 9 days for those randomized to surgery. In
both groups, there was greater variation in the median time
to return to the participation behaviours than the activity
behaviours.
Endovenous laser ablation versus surgery
Participants randomized to EVLA recalled being able to
carry out 13 of the 15 behaviours significantly more quickly
than those randomized to surgery (Table 3). Return to ‘hav-
ing a bath or shower’ was quicker after surgery than after
EVLA. There was no difference in time to return to the
participation behaviour of ‘wearing clothes that show the
legs’.
Endovenous laser ablation versus
ultrasound-guided foam sclerotherapy
There were no differences in the time taken to return
to 11 of the 15 behaviours between participants random-
ized to EVLA and those randomized to UGFS (Table 4).
Return to ‘walking short distances without discomfort’,
‘walking long distances’, ‘looking after children’ and ‘full
return to normal work/employment’ took longer for the
EVLA group than the UGFS group. Following UGFS or
EVLA only one-third of the specific behaviours could be
carried out by 50 per cent of participants by 3 days after
treatment.
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Discussion
This study showed that both UGFS and EVLA resulted in
a more rapid recovery compared with surgery for 13 of the
15 behaviours. UGFS was superior to EVLA in terms of
return to full time work, looking after children and walking
(both short and long distances). Importantly, the specific
behaviours assessed were shown to have a range of different
recovery trajectories.
Previous randomized clinical trials showed behavioural
recovery to be more rapid following UGFS compared with
surgery1,2, but the benefit of EVLA over surgery was less
clear2,4,8 . In this study, for all but two behaviours (wearing
clothes that showed the legs and showering/bathing) the
recovery was quicker following UGFS or EVLA compared
with surgery. These findings may have arisen as a result
of information contained in the study PIL, which recom-
mended that compression hosiery was worn continuously
for 10 days following UGFS or EVLA but for 4–5 days
routinely after surgery.
In the comparison between UGFS and EVLA,
behavioural recovery was faster following UGFS for
four of the 15 behaviours; there was no difference between
the groups for the other behaviours. Two previous random-
ized trials2,3 showed earlier return to ‘normal activities’
in patients undergoing UGFS compared with EVLA.
Specifically, the present study showed a quicker return to
full-time work following UGFS, similar to the findings
of Rasmussen and colleagues2. The median time taken to
return to work following EVLA (7⋅7 days) was within the
ranges reported2,4–8.However, Rasmussen and colleagues2
reported earlier return to work after UGFS compared with
the present study (median 2⋅9 versus 4⋅8 days respectively).
A partial explanation of the difference between the two
studies may be that, unlike the previous study, the present
analysis did not correct for weekends.
For other behaviours, the recalled recovery times follow-
ing both UGFS and EVLA were longer than might be
expected from the literature2–5,8. This may be explained
by the timing of the questionnaire at 6weeks, and thus
it is the nature of the differences between treatment
groups rather than the absolute timings taken to return to
these activities that the authors wish to highlight in this
paper.
The extent of this overall delay in recovery is hard to jus-
tify, particularly in light of the standard information and
advice given in the study PIL. There may have been a
number of external influences affecting participants’ rec-
ollection of their recovery, including misinformation and
fear. Although attitudes to recovery and return to nor-
mal behaviours have changed in secondary care, this may
not have filtered into primary care or ‘public knowledge’.
Fear of activity or fear of pain caused by activity has been
documented following surgery for other conditions17,18.
It is possible that some people undergoing treatment for
varicose veins experience similar fears, and this may limit or
restrict their activity following treatment. With regard to
return to work, there are clearly a number of additional fac-
tors that might play a role, such as a person’s employment
status (employed or self-employed), the sickness benefits
they are entitled to, the type of work they are employed
to do, how long they are ‘signed off’ by the doctor, and
the views of their employer on return to work after an
operation. It should be noted that this study distinguished
between partial and full return to work, and that no differ-
ence was noted in partial return to work following UGFS
and EVLA. This finding may be of substantial impor-
tance to patients, their employers and the economy as
a whole.
The main strength of this study is that the behaviours
investigated were based on systematic investigation of the
recovery milestones that are important to patients fol-
lowing treatment for varicose veins. Hence, the findings
are of personal importance from a patient perspective.
Distinguishing between the behaviours that contribute to
‘normal activity’ helps build a profile of recovery that
may be particularly useful for patients preparing for, or
recovering from, treatment. Furthermore, the methodol-
ogy used to develop the BRAVVO questionnaire could be
used in other conditions to provide normative informa-
tion about behavioural recovery that is relevant to patients.
The BRAVVO questionnaire was pilot tested and found to
be acceptable to patients, comprehensible and appropriate
for self-completion. Despite this, a potential weakness of
the study is that the level of missing data in the BRAVVO
questionnaire was higher for two of the questions. Further
work to reformat or rephrase the questions or response
options may help minimize levels of missing data. A fur-
ther potential weakness is the choice of assessment time
point (6weeks after treatment). This may have compro-
mised recall, particularly for behaviours that participants
were able to return to a short time after treatment; how-
ever, any compromise in recall is likely to have affected the
three treatment groups equally.Other study outcomeswere
assessed at 6weeks, and behavioural recovery was assessed
at the same time point tominimize participant burden. Fur-
ther work is required to determine the optimal timing(s) of
this questionnaire. Given that the median time to return to
the behaviour was less than 14 days for 13 of the behaviours,
and up to 22 days for the other two (wearing clothes that
show the legs, sporting activity or exercise), the use of
the questionnaire at approximately 2–3weeks would seem
appropriate.
© 2016 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2016; 103: 374–381
on behalf of BJS Society Ltd.
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